Head & neck · 2026
Bone-Anchored Implant Survival in Oncologic Facial Prosthetic Rehabilitation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Blanshard Oliver, Jones Sarah, Clarke Peter M, Bernstein Jonathan M
Аннотация
BACKGROUND: Published survival rates for bone-anchored craniofacial implants exceed 85%, but derive largely from mixed populations. Whether these apply to head and neck oncologic surgery remains uncertain.
METHODS: Retrospective survival analysis of implants placed for prosthetic rehabilitation following extirpative surgery at a UK center (2005-2024).
RESULTS: Survival among 184 implants in 51 patients was 94%, 60% and 46% at 1, 3 and 5 years (median 4.1 years, 95% CI 3.0-6.3). 77% of patients received radiation therapy. Median dose to implant region was 57 Gy. On univariate analysis, radiation, diabetes and older age predicted implant loss. On multivariable analysis, diabetes, present in three patients, predicted implant loss (HR 4.0, 95% CI 1.5-10.7), while radiation therapy trended towards implant loss. Annual hazard rates demonstrated continual attrition without plateau.
CONCLUSIONS: Five-year survival in this oncologic cohort was half the published rate. Ongoing attrition supports supernumerary implant placement and lifelong management.
METHODS: Retrospective survival analysis of implants placed for prosthetic rehabilitation following extirpative surgery at a UK center (2005-2024).
RESULTS: Survival among 184 implants in 51 patients was 94%, 60% and 46% at 1, 3 and 5 years (median 4.1 years, 95% CI 3.0-6.3). 77% of patients received radiation therapy. Median dose to implant region was 57 Gy. On univariate analysis, radiation, diabetes and older age predicted implant loss. On multivariable analysis, diabetes, present in three patients, predicted implant loss (HR 4.0, 95% CI 1.5-10.7), while radiation therapy trended towards implant loss. Annual hazard rates demonstrated continual attrition without plateau.
CONCLUSIONS: Five-year survival in this oncologic cohort was half the published rate. Ongoing attrition supports supernumerary implant placement and lifelong management.